Cardiac Pacemaker Market Is Growing With the Increasing Incidence of Cardiovascular Diseases
Active implantable medical devices, such as cardiac
pacemakers, are medical devices designed to be introduced totally or partially into
the human body for diagnostic or therapeutic purposes. A cardiac pacemaker is a
small, battery-operated device that helps to regulate the heart rate. A cardiac
pacemaker senses when the heart beats irregularly or very slowly and helps the
heart beat regularly. In the past, Magnetic resonance imaging (MRI) was not
allowed in patients with implanted cardiac pacemakers. However, technological
advancements have made it possible. MRI can now be safely performed in patients
with cardiac pacemakers. In the United States, many medical device companies
have received Food and Drug Administration (FDA) approval and have launched
pacemakers that are MRI compatible.
Market Dynamics:
With the increasing incidence of cardiovascular diseases (CVDs)
worldwide, the demand for cardiac pacemaker is also increasing, driving the
growth of the cardiac
pacemaker market. According to the World Health Organization (WHO), cardiovascular
diseases are the leading cause of death worldwide. Moreover, according to the
American College of Cardiology, in the U.S., coronary events were expected to
occur in around 1,055,000 individuals in 2019, including 720,000 new and
335,000 recurrent coronary events.
Furthermore, technological advancements in cardiac pacemakers
and increasing adoption of technologically advanced products are expected to
offer lucrative growth opportunities for players in the cardiac pacemaker market.
For instance, in October 2020, Medtronic launched the Azure pacemaker with
BlueSync technology, only pacemaker that can communicate directly with patients’
smartphones and tablets. Azure is designed to accurately detect and reduce the
likelihood of atrial fibrillation.
Asia Pacific is expected to witness robust growth in the cardiac
pacemaker market due to increasing prevalence of cardiovascular diseases and
growing adoption of technologically advanced products in the region. For
instance, in Chine, more than 700 patients have been implanted with the world's
smallest leadless cardiac pacemaker (FDA-approved), which was officially
launched in the market by Medtronic in January 2020.
Competitive Analysis:
Major players operating in the cardiac pacemaker market are Medtronic, Cordis Inc., Qinming
Medical, LivaNova PLC, BIOTRONIK, Inc., Lepu Medical Technology Co Ltd., MEDICO
S.p.A., Shree Pacetronix Ltd., Vitatron Holding B.V., Abbott Laboratories, and
Boston Scientific Corporation.
Major players in the market are adopting various inorganic
strategies to strengthen their product portfolio or market position. For
instance, in July 2020, Abbott secured approvals from the FDA for its new
generation of connected pacemakers and defibrillator implants.
In January 2019, Medtronic launched MyCareLink Heart mobile
app to support the world's first and only portfolio of pacemakers that can
communicate directly with patients' smartphones and tablets.

Comments
Post a Comment